Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DDX3X | O00571 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9687046 | 0.87 | KDM4E (0.48) | NLRP3NPC1RAB9AHTTUTS2R | |
| SCHEMBL5839856 | 0.83 | HPGD (0.49) | NLRP3NPC1RAB9AHTTKMT2A | |
| SCHEMBL9686207 | 0.76 | ALDH1A1 (0.59) | NLRP3NPC1RAB9AHTTKMT2A | |
| SCHEMBL9685813 | 0.75 | LCK (0.45) | NLRP3NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL9686605 | 0.73 | ALDH1A1 (0.66) | NPC1RAB9AKMT2AHPGDALDH1A1 | |
| SCHEMBL9685670 | 0.72 | POLB (0.54) | NPC1RAB9AHTTKMT2AHPGD | |
| SCHEMBL9687318 | 0.70 | NPC1 (0.76) | NLRP3NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL11798134 | 0.70 | NPC1 (0.58) | NPC1RAB9AUTS2RHPGDALDH1A1 | |
| SCHEMBL9686399 | 0.70 | ALDH1A1 (0.60) | NPC1RAB9AHPGDALDH1A1L3MBTL1 | |
| SCHEMBL9685750 | 0.70 | NPC1 (0.53) | NPC1RAB9AHPGDALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141567-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20060035892-A1 | Nitrosated imidazopyridines | ATLANTA PHARMA AG (DE) | 2006-02-16 | — | — | US | disclosed |
| US-6869949-B2 | Polysubstituted imidazopyridines as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2005-03-22 | — | — | US | disclosed |
| EP-1504003-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2005-02-09 | — | — | EP | disclosed |
| US-20040214852-A1 | Polysubstituted imidazopyridines | ALTANA PHARMA AG (DE) | 2004-10-28 | — | — | US | disclosed |
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2004-06-03 | — | — | US | disclosed |
| WO-2003091253-A1 | NITROSATED IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | disclosed |
| EP-1332143-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA Pharma AG (DE) | 2003-08-06 | — | — | EP | disclosed |
| US-6384048-B1 | GASTROINTESTINAL DISORDERS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2002-05-07 | — | — | US | disclosed |
| WO-2002034749-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2002-05-02 | — | — | WO | disclosed |
| EP-1127059-A1 | IMIDAZONAPHTHYRIDINES | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026217-A1 | IMIDAZONAPHTHYRIDINES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106642-A1 | POLYSUBSTITUTED IMIDAZOPYRIDINES AS GASTRIC SECRETION INHIBITORS | GIPR, SLC10A2, VIP | NLRP3 4576/4885NPC1 1576/4885RAB9A 1893/4885 |
| US-20060035892-A1 | Nitrosated imidazopyridines | NOS2, NOS1, NOS3 | NLRP3 998/4885NPC1 3177/4885RAB9A 2105/4885 |
| US-20040214852-A1 | Polysubstituted imidazopyridines | GIPR, VIP, SLC10A2 | NLRP3 4712/4885NPC1 1702/4885RAB9A 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.